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Abstract 
The breakdown of blood-tear barrier that occurs with ocular pathology allows for large amounts of 
albumin to leak into the tear fluid. This process likely represents an important restriction to drug 
absorption in ophthalmology, as only the unbound drug is transported across the ocular tissue barriers to 
exert its pharmacologic effect. We aimed to investigate the effects of albumin levels in tears on the 
bioavailability of two commonly used ophthalmic drugs: tropicamide, an antimuscarinic that produces 
mydriasis and cycloplegia, and latanoprost, a PGF2α analog used for the treatment of glaucoma. Eight 
female beagle dogs underwent a randomized, vehicle-controlled crossover trial. For each dog, one eye 
received 30 µl of artificial tears (control) or canine albumin (0.4 or 1.5%) at random, immediately followed 
by 30 µl of 1% tropicamide (2 days, 24 h washout) or 0.005% latanoprost (2 days, 72 h washout) in both 
eyes. Pupil diameter (digital caliper) and intraocular pressure (IOP; rebound tonometry) were recorded at 
various times following drug administration (0 to 480 min) and compared between both groups with a 
mixed model for repeated measures. Albumin in tears had a significant impact on pupillary diameter for 
both tropicamide (P ≤ 0.001) and latanoprost (P ≤ 0.047), with no differences noted between 0.4% and 
1.5% concentrations. Reduction in the maximal effect (pupil size) and overall drug exposure (area under 
the effect time-curve of pupil size over time) were significant for tropicamide (6.2–8.5% on average, P ≤ 
0.006) but not for latanoprost (P ≥ 0.663). The IOP, only measured in eyes receiving latanoprost, was not 
significantly impacted by the addition of either 0.4% (P = 0.242) or 1.5% albumin (P = 0.879). Albumin in 
tear film, previously shown to leak from the conjunctival vasculature in diseased eyes, may bind to 
topically administered drugs and reduces their intraocular penetration and bioavailability. Further 
investigations in clinical patients and other commonly used ophthalmic medications are warranted. 
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The breakdown of blood-tear barrier that occurs with ocular pathology allows for large
amounts of albumin to leak into the tear fluid. This process likely represents an important
restriction to drug absorption in ophthalmology, as only the unbound drug is transported
across the ocular tissue barriers to exert its pharmacologic effect. We aimed to investigate
the effects of albumin levels in tears on the bioavailability of two commonly used
ophthalmic drugs: tropicamide, an antimuscarinic that produces mydriasis and
cycloplegia, and latanoprost, a PGF2a analog used for the treatment of glaucoma.
Eight female beagle dogs underwent a randomized, vehicle-controlled crossover trial.
For each dog, one eye received 30 µl of artificial tears (control) or canine albumin (0.4 or
1.5%) at random, immediately followed by 30 µl of 1% tropicamide (2 days, 24 h washout)
or 0.005% latanoprost (2 days, 72 h washout) in both eyes. Pupil diameter (digital caliper)
and intraocular pressure (IOP; rebound tonometry) were recorded at various times
following drug administration (0 to 480 min) and compared between both groups with
a mixed model for repeated measures. Albumin in tears had a significant impact on
pupillary diameter for both tropicamide (P ≤ 0.001) and latanoprost (P ≤ 0.047), with no
differences noted between 0.4% and 1.5% concentrations. Reduction in the maximal
effect (pupil size) and overall drug exposure (area under the effect time-curve of pupil size
over time) were significant for tropicamide (6.2–8.5% on average, P ≤ 0.006) but not for
latanoprost (P ≥ 0.663). The IOP, only measured in eyes receiving latanoprost, was not
significantly impacted by the addition of either 0.4% (P = 0.242) or 1.5% albumin (P =
0.879). Albumin in tear film, previously shown to leak from the conjunctival vasculature in
diseased eyes, may bind to topically administered drugs and reduces their intraocular
penetration and bioavailability. Further investigations in clinical patients and other
commonly used ophthalmic medications are warranted.
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INTRODUCTION
Topical instillation is the most common route of drug
administration in ophthalmology, especially for the treatment
of anterior segment diseases (Gaudana et al., 2010). This mode of
administration is convenient and non-invasive, although drug
bioavailability is generally poor (typically < 10%) due to
physiological, structural, and biochemical barriers to drug
penetration into the eye (Järvinen et al., 1995; Gaudana et al.,
2010; Bucolo et al, 2012). Upon instillation, an eyedrop is
immediately diluted in the tear film and a large portion of the
drug is lost through reflex tearing, nasolacrimal drainage, and
systemic absorption. Residual drug has to cross ocular tissue
barriers (i.e. cornea, sclera, and conjunctiva) to reach targets
within the globe (Prausnitz and Noonan, 1998; Gaudana et al.,
2010; Bucolo et al, 2012). In general, small lipophilic drugs
permeate through the cornea while larger or hydrophilic
compounds permeate through the conjunctiva and sclera
(Prausnitz and Noonan, 1998). Protein binding in tear film
represents another important restriction to drug absorption, as
only the unbound drug is transported across the tissue barriers
(Mikkelson et al., 1973a). In fact, the presence of albumin in tears
can dramatically reduce the bioavailability of topical drugs via
protein-drug interactions, as previously shown for pilocarpine in
rabbit eyes (Mikkelson et al., 1973a).
Albumin is a relatively large (66 kDa) and negatively charged
protein that is widely distributed in the body. Given the protein’s
remarkable capacity for binding ligands (de Wolf and Brett, 2000),
albumin serves as a reservoir and transporter for drugs and other
molecules such as hormones, metabolites, and nutrients. At the
level of the eye, plasma-derived albumin leaks onto the ocular
surface from conjunctival vessels and mixes with the tear film
(Runstrom et al., 2013). Albumin concentration in tears is generally
low in healthy state but increases substantially in diseased eyes
(Runstrom et al., 2013). In fact, albumin is often considered a
biomarker of ocular insult or inflammation as the breakdown of
blood-tear barrier noted with ocular pathology allows for large
amounts of albumin to leak into the lacrimal fluid (Anderson and
Leopold, 1981; Woodward and Ledgard, 1985; Runstrom et al.,
2013). A recent study by Sebbag et al. showed that canine eyes with
diverse ocular diseases (e.g. corneal ulcer, uveitis, glaucoma) had
lacrimal albumin levels that were up to 14.9-fold greater than
contralateral healthy eyes (Sebbag et al., 2019a).
The impact of albumin binding on the drug’s pharmacological
activity is extensively studied in blood (Zhivkova, 2015), yet
little is known about the physiology and function of albumin in
tears or other biological fluids. In the present study, we examined
the bioavailability of topically delivered drugs in the presence of
clinically relevant levels of albumin in tears (Sebbag et al., 2019a).
Wehypothesized that thedrugs’ intraocular effectwill be reducedby
lacrimal albumin given the inability of protein-bound drugs to
permeate through ocular tissue barriers. Two ophthalmic
medications were investigated as a proof-of-concept experiment:
0.005% latanoprost and 1% tropicamide. These drugs are
commonly used in human and veterinary practice, and possess
different physicochemical properties (e.g. solution pH, drug
concentration) that could influence protein-drug interactions.
Latanoprost, a PGF2a analog, is used for the treatment of
glaucoma and ocular hypertension in human and veterinary
patients (Stjernschantz, 2001; Willis et al., 2002). Tropicamide, an
antimuscarinic drug, is used to achieve short-acting mydriasis for
enhanced visualization of the lens, vitreous body, and fundus, as
well as cycloplegia to control accommodation during the
assessment of refractive error (Manny et al., 2001). Pupil response
to tropicamide was also suggested as a noninvasive neurobiological
test for Alzheimer’s disease and other neurodegenerative disorders
(Scinto et al., 1994; Gómez-Tortosa et al., 1996), although this
diagnostic test fell out of favor given large inter- and intra-
individual variations and subsequent poor test specificity
(Reitner et al., 1997). Drug binding to proteins in tear fluid could
partly explain the aforementioned variability in pupil size, a
phenomenon our group investigated in the present study to help
guide future diagnostic and therapeutic applications in
ophthalmology. The present work was conducted in dogs, a
species that represents an excellent large animal model for
translational research in humans given similarities in ocular
anatomy (Vézina, 2013) and physiologic parameters pertinent to
topical route of drug administration (Sebbag et al., 2019b, Sebbag
et al., 2019c), as well as spontaneous disease development such
as glaucoma (Grozdanic et al., 2010), dry eye (Kaswan et al., 1989)
and conjunctivitis (Sebbag et al., 2019a).
MATERIALS AND METHODS
Animals
Eight female spayed Beagle dogs (1.5–2.0 years, 7.5–10 kg) were
recruited. Prior to study enrollment, dogs were part of a teaching
colony and underwent weekly physical and ophthalmic
examinations, including tonometry (TonoVet, Icare Finland
Oy, Espoo, Finland). At study inclusion, dogs were confirmed
to be healthy based on a complete physical and ophthalmic
examination, including tonometry (TonoVet), Schirmer tear
test-1 (STT-1; Eye Care Product Manufacturing LLC, Tucson,
AZ, USA), slit-lamp biomicroscopy (SL-17; Kowa Company,
Ltd., Tokyo, Japan), and indirect ophthalmoscopy (Keeler
Vantage; Keeler Instruments, Inc., Broomall, PA, USA). The
study was approved by the Institutional Animal Care and Use
Committee of Iowa State University (protocol #19-049), and
conducted in accordance with the Association for Research in
Vision and Ophthalmology guidelines for animal use.
Experiment
Two canine albumin ophthalmic solutions (0.4% and 1.5%) were
formulated by mixing canine albumin lyophilized powder (Animal
Blood Resource International, Stockbridge, MI) with lubricating eye
drops (Artificial tears solution, Rugby, Rockville Center, NY, USA)
in a sterile manner under a laminar flow hood. Of note, albumin
concentrations selected herein (0.4% and 1.5%) aimed to achieve
tear film albumin levels of ~ 1 to 5 mg/ml (i.e., after dilution of the
instilled drop with the canine tear film, accounting for ~ 3-fold
dilution; Sebbag et al., 2019b), thus representing a spectrum of
albumin levels in tears of dogs with spontaneous or experimentally-
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induced conjunctivitis (Sebbag et al., 2019a). Artificial tears solution
without albumin (vehicle only) was used as control for the
experiment. Albumin and vehicle solutions were kept in the
refrigerator (4°C) and used within 7 days of preparation.
For each dog, one eye was randomly selected to receive
albumin solutions while the contralateral eye served as control
(vehicle solution); this choice was kept constant throughout the
study. Tropicamide 1% (Sandoz Inc., Princeton, New Jersey, USA)
and latanoprost 0.005% (Sandoz Inc., Princeton, New Jersey, USA)
were each investigated over two separate days. To allow pupil size
to return to baseline and avoid a carry-over effect, the washout
between experimental days was 24 h for tropicamide (Rubin and
Wolfes, 1962) and 72 h for latanoprost (Pirie et al., 2011). For each
drug, the eye allocated to albumin was randomly assigned to
receive either 4 mg/ml or 15 mg/ml albumin solution on the first
experimental day, and vice versa on the second day.
The experiments took place in a quiet and uniformly
illuminated room (500 lux) under controlled temperature (70–
72°F) and ambient humidity (25–30%). Measurements of pupil
diameter (PD) were obtained with a digital Vernier caliper
(± 0.01 mm, Ultratech No. 1433, General Tools & Instruments,
Secaucus, NJ) held adjacent to the cornea, while measurements
of intraocular pressure (IOP) were obtained with rebound
tonometry (TonoVet, Icare Finland Oy, Espoo, Finland).
Baseline PD and IOP were recorded in both eyes of each dog
at the beginning of each study day.
Using a pipette, 30 µl of experimental solution were delivered
topically: albumin in one eye, vehicle in the other. This was
immediately followed (< 10 sec) by topical instillation of 30 µl of
the drug (tropicamide or latanoprost) in both eyes. Then, PD
(tropicamide and latanoprost) and IOP (latanoprost only) were
recorded in both eyes at the following time points: 2, 4, 6, 8, 10,
15, 20, 30, 45, 60, 90, 120, 180, 240, and 480 min.
Data Analysis
Normality of data was assessed with the Shapiro-Wilk test.
Differences in pupil diameter (tropicamide, latanoprost) and
IOP (latanoprost) between eyes receiving vehicle (control) or
albumin (0.4 or 1.5%) were assessed with a mixed model for
repeated measures (MMRM) using the R software version 3.6.0
(Lee et al., 2018). In the model, PD or IOP were the response
variable, the group (control or albumin), time (0 to 480 min) and
group-by-time interaction were treated as fixed effects, and the
animal and animal-by-group interaction were treated as random
effects, using animal as block. After the model was fit, the fixed
effects were tested, and comparisons between control and albumin
eyes at baseline and each time point were made. The R software
was also used to calculate the area under the effect-time curve
(AUETC) and the maximal effect on pupil diameter (maximal
dilation for tropicamide, maximal constriction for latanoprost).
Paired t-tests were conducted with SigmaPlot 14.0 (Systat Software
Inc., San Jose, CA, USA) to assess the following parameters: (i)
AUETC for tropicamide and latanoprost, (ii) PDmax for
tropicamide, and (iii) PDmin for latanoprost. P values < 0.05
were considered statistically significant.
RESULTS
Results from the Shapiro-Wilk test confirmed that the
experimental data were normally distributed. Results are
therefore presented as mean ± standard deviation (SD).
Pupil Dilation From Tropicamide
Taking the variable “time” into account, albumin had a
significant effect on pupil diameter post- tropicamide
administration for both 0.4% (P = 0.001) and 1.5%
concentrations (P = 0.001). Compared to the contralateral eye
(control), pupillary dilation was significantly reduced in eyes
receiving 0.4% albumin as early as 8 min (P = 0.043) and as late
as 240 min (P = 0.009) (Figure 1A), and in eyes receiving 1.5%
albumin as early as 8 min (P = 0.027) and as late as 240 min (P =
0.021) (Figure 1B) following instillation of 1% tropicamide. A
representative clinical image is depicted in Figure 2, showing a
lower degree of mydriasis in the dog’s left eye (0.4% albumin and
1% tropicamide) compared to the right eye (artificial tears and
1% tropicamide) at 45 min following eyedrop administration.
Further, the cumulative effect of tropicamide on pupillary
FIGURE 1 | Mean + SD pupil diameter from 0 to 480 min in dogs receiving 1% tropicamide in both eyes, immediately preceded by topical instillation of artificial
tears (control, white circles) in one randomly selected eye, and either 0.4% albumin (A, black triangles) or 1.5% albumin (B, black triangles) in the other eye. Statistical
differences (P < 0.05) obtained with mixed model for repeated measures are depicted by gray asterisks (*).
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dilation (from 0 to 480 min) was significantly reduced with the
addition of 0.4% or 1.5% albumin (P < 0.001), representing an
average reduction in biological response of 7.1% and 7.2%
compared to controls, respectively (Figure 3); however, no
differences were noted in AUETC (pupil size over time)
between both albumin concentrations (P = 0.842). Last, mean
± SD maximal pupillary dilation in eyes receiving tropicamide
and 0.4% albumin (11.9 ± 0.7 mm) or 1.5% albumin (11.7 ± 1.3
mm) was significantly lower (P ≤ 0.006) compared to
contralateral controls (12.7 ± 0.8 mm, and 12.8 ± 1.1 mm,
respectively), representing a reduction in biological response of
6.2% and 8.5%, respectively (Figure 4).
Pupil Constriction From Latanoprost
Taking the variable “time” into account, albumin had a
significant effect on pupil diameter post- latanoprost
administration for both 0.4% (P = 0.016) and 1.5%
concentrations (P = 0.047). Compared to the contralateral eye
(control), pupillary constriction was overall reduced in eyes
receiving 0.4% albumin (Figure 5A) or 1.5% albumin
(Figure 5B), although differences in pupil diameter were not
statistically significant at any time point following instillation of
0.005% latanoprost (P ≥ 0.158 and P ≥ 0.416, respectively). No
differences were noted in AUETC (pupil size over time) between
groups (P ≥ 0.663), nor in maximal pupillary constriction (P =
1.000) obtained with 0.4% albumin (1.5 ± 0.1 mm), 1.5%
albumin (1.5 ± 0.2 mm), and their respective contralateral
controls (1.5 ± 0.1 mm and 1.5 ± 0.2 mm).
IOP Changes From Latanoprost
Compared to the contralateral eye (control), IOP was
significantly lower in eyes receiving 0.4% albumin at 10 min
(P = 0.010), 20 min (P = 0.010), 45 min (P = 0.010), and 240 min
(P = 0.010) following instillation of 0.005% latanoprost (Figure
6A), while no significant changes were noted at any time point
(P ≥ 0.262) for the 1.5% albumin group (Figure 6B). However,
after taking “time” into account in the mixed effects model, it is
important to note that the impact of albumin on IOP was not
statistically significant for either 0.4% (P = 0.242) or 1.5%
concentration (P = 0.879). Further, no differences were noted
in AUETC (IOP over time) between control and albumin groups
(P ≥ 0.351) or between both albumin groups (P = 0.979).
DISCUSSION
The bioavailability of ophthalmic drugs can be reduced by the
presence of albumin in tears, a protein that leaks onto the ocular
FIGURE 2 | Clinical image of a Beagle dog at 45 min following topical
instillation of 1% tropicamide in both eyes, immediately preceded by topical
artificial tears (right eye, control) and 0.4% albumin (left eye). Note the lower
degree of mydriasis in the left eye.
FIGURE 3 | Box-and-whisker plots depicting the area under the effect-time curve (AUETC) of pupil diameter over time (0 to 480 min) in dogs receiving 1%
tropicamide in both eyes, immediately preceded by topical instillation of artificial tears (control, white boxes) in one randomly selected eye, and either 0.4% albumin
(light gray box) or 1.5% albumin (dark gray box) in the other eye. Mean and median values are shown by horizontal dotted and solid lines, respectively. First and third
quartiles (25th and 75th percentiles) are represented by the lower and upper limits of the box, respectively, while the 2.5th and the 97.5th percentiles are shown as
the lower and upper whiskers, respectively.
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FIGURE 4 | Box-and-whisker plots depicting the maximal pupillary diameter in dogs receiving 1% tropicamide in both eyes, immediately preceded by topical
instillation of artificial tears (control, white boxes) in one randomly selected eye, and either 0.4% albumin (light gray box) or 1.5% albumin (dark gray box) in the other
eye. Mean and median values are shown by horizontal dotted and solid lines, respectively. First and third quartiles (25th and 75th percentiles) are represented by the
lower and upper limits of the box, respectively, while the 2.5th and the 97.5th percentiles are shown as the lower and upper whiskers, respectively.
FIGURE 5 | Mean + SD pupil diameter from 0 to 480 min in dogs receiving 0.005% latanoprost in both eyes, immediately preceded by topical instillation of artificial
tears (control, white circles) in one randomly selected eye, and either 0.4% albumin (A, black triangles) or 1.5% albumin (B, black triangles) in the other eye. No
statistical differences were noted between groups at any time point (mixed model for repeated measures, P ≥ 0.05).
FIGURE 6 | Mean + SD intraocular pressure from 0 to 480 min in dogs receiving 0.005% latanoprost in both eyes, immediately preceded by topical instillation of
artificial tears (control, white circles) in one randomly selected eye, and either 0.4% albumin (A, black triangles) or 1.5% albumin (B, black triangles) in the other eye.
Statistical differences (P < 0.05) obtained with mixed model for repeated measures are depicted by gray asterisks (*).
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surface in large amounts in the diseased eye. A deeper
understanding of albumin-drug interactions in tears is critical
to basic researchers in pharmacology and vision science, but also
physicians and veterinarians. Indeed, drug binding to albumin
may partly explain the challenge of treating certain diseases in
ophthalmology. For instance, a poor response of uveitis to topical
corticosteroid may be due to high affinity of the drug to albumin
in tears, while a poor response of infectious keratitis to topical
antibiotics may be explained by the fact that only the unbound
portion of an antimicrobial is microbiologically active (Dalhoff,
2018). Here, we showed a differential impact of albumin in tears
on the ocular response of tropicamide and latanoprost, two
common ophthalmic drugs in human and veterinary patients,
and the same could be investigated in the canine model for other
relevant drug classes. Dogs are particularly suited for
translational research in ocular pharmacology as—unlike small
laboratory animals—dogs share similar anatomical and
physiological features to humans, similar environmental
stressors and genetic variation, and a range of naturally
occurring ophthalmic diseases that resemble the ones
diagnosed in human patients.
Ocular Response of Tropicamide and
Latanoprost in the Presence of Albumin
The biological effect of tropicamide (i.e. mydriasis) was
significantly reduced in canine eyes that received concurrent
topical administration of serum albumin, regardless of the
protein’s concentration. Albeit minimal (6.2–8.5%), the impact
of albumin on tropicamide-induced pupillary dilation is likely
underestimated compared to clinical patients given limitations
inherent to the study design (described below). Interestingly, this
lower degree of tropicamide-induced mydriasis was also noted in
canine eyes covered with a soft contact lens, a physical barrier to
drug penetration (Hatzav et al., 2016). Similar findings were
noted by Mikkelson et al. in rabbit eyes receiving pilocarpine
(Mikkelson et al., 1973a), although the magnitude of drug-
response reduction was much greater in rabbits (75–100 fold)
compared to the present study in dogs (6–8%). Such discrepancy
is likely explained by two important differences in study designs.
In the present experiment, the concentrations of albumin (0.4%
and 1.5%) were specifically chosen based on clinically-relevant
albumin levels detected in canine patients with diverse ocular
diseases (Sebbag et al., 2019a), taking into account the threefold
dilution effect from resident tears (Sebbag et al., 2019b) to better
account for the true binding constant seen in dialysis
experiments (Chrai and Robinson, 1976). In contrast, the
concentrations of albumin used in rabbits were higher (1% and
3%) and may not reflect the range of biological concentrations of
albumin at the ocular surface. Another key difference is the way
albumin was delivered to the ocular surface. While albumin was
pre-mixed with pilocarpine solution in the rabbit study, allowing
for protein-drug binding to occur ex situ (i.e. away from the
ocular surface) over an extended duration, albumin and
tropicamide were delivered separately in the present study
(albumin first, tropicamide within <10 s) so that protein-drug
interactions would occur in-situ (i.e. in the tear film) over a short
duration. From a physiological standpoint, the latter method is
more appropriate as the interaction time of a topical drug to
albumin in tears is generally short, limited by the rapid tear
turnover rate that occurs following eyedrop administration in
dogs (Sebbag et al., 2019c) or other species (Shell, 1982; Wilson,
1999). Of note, tonometry was not performed in dogs receiving
tropicamide (with or without albumin) in the present study given
the lack of effect of tropicamide on IOP in healthy canine eyes
(Jugant et al., 2019), but this parameter could be considered in
future studies as IOP can vary from tropicamide in dogs
receiving sedation (Jugant et al., 2019) or dogs with
glaucomatous eyes.
The pharmacological activity of latanoprost (i.e. miosis) was
also reduced in the presence of albumin in tears, although not to
the same extent as for tropicamide. Indeed, differences in pupil
size between albumin and control eyes were limited in duration
(up to 30 min, compared to 240 min for tropicamide) and
somewhat limited in magnitude (1% non-significant change in
AUETC). These findings are likely explained by the high
sensitivity of the iris sphincter muscle to the drug (Yoshitomi
and Ito, 1988). The minimum amount of PGF2a required to
generate contraction of the iris sphincter in dogs is 10-10 M
(Yoshitomi and Ito, 1988), while the concentration of
latanoprost applied topically is approximately 106 higher
(0.005% ~ 10-4 M). The amount of drug lost to albumin in
tears is therefore insignificant, as only a small fraction of
intraocular drug penetration is sufficient to cause miosis.
Furthermore, once latanoprost reaches the anterior chamber,
the drug acts directly on the iris sphincter muscle but also
indirectly through the release of endogenous prostaglandins
(Yousufzai et al., 1996; Bergh et al., 2002). Endogenous
PGF2a, which further acts on the prostanoid FP receptors and
contributes to the sphincter muscle’s tone in dogs (Yoshitomi
and Ito, 1988), is released inside the anterior chamber and is
thereby not affected by albumin levels in the tear film.
Following latanoprost administration, the overall effect of
lacrimal albumin on IOP values was non-significant for either
albumin concentration. Compared to control eyes, a significantly
lower IOP was noted at selected times (10, 20, 45, and 240 min)
in eyes receiving 0.4% albumin concurrently to latanoprost,
although it is important to note that IOP readings displayed a
large variability within—and between—subjects in all groups. To
reduce IOP variability, a recent study in healthy Beagle dogs
(Fentiman et al., 2019) recommended a minimum offive training
days immediately prior to the start of the study, and collecting
IOP readings in triplicate at each time. In absence of such
precautions, the IOP results of the present study are likely
confounded by a large measurement noise.
Factors Affecting the Impact of Albumin
on Drug Bioavailability
The present findings provide evidence that albumin levels in
tears does not affect all drugs in a uniform manner. Rather, the
mechanism of action of a drug and/or potency for its biological
target can modulate the impact of lacrimal albumin on the drug’s
pharmacological activity. The dose-response relationship, a
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cornerstone of pharmacology/toxicology, defines the role of a
dose for a chemical (e.g. drug, toxic agent) in evoking biological
response (Snyder, 1984). Figure 7A depicts two drugs (A and B)
with different dose-response profiles. In this scenario, if lacrimal
albumin reduces the amount of free drug available inside the eye
by 50%, the response observed (e.g. pupillary dilation) will be
greatly reduced for drug B but minimally affected for drug A.
Along the same line, the amount of drug applied topically is an
important factor to take into consideration. For a given drug, if
the dose administered topically falls in the “far right” of the
drug’s dose-response curve, a reduction in drug available after
albumin binding would only minimally affect the observed
response (dose X, Figure 7B); in contrast, if the dose delivered
produces an effect that falls within the steep portion of the dose-
response curve, the impact of dose reduction from albumin
would be more pronounced (dose Y, Figure 7B). Mikkelson
and colleagues showed that the entire biological response
(pilocarpine-induced miosis) could be suppressed when low
drug concentrations were used in the presence of serum
albumin (Mikkelson et al., 1973a). Future studies leveraging
this work should assess the ocular response obtained from
different concentrations of the same drug (e.g. tropicamide
0.05%, 0.5%, 1%, 2%) in the presence of albumin in tears.
A number of other factors can influence the drug-protein
interactions on the ocular surface, including albumin
concentrations in tears and physicochemical properties of the
individual drug. In plasma, higher levels of albumin can further
reduce the biological response of a drug, as exemplified by lower
antimicrobial activity of fluoroquinolones with increasing levels
of serum albumin (Zeitlinger et al., 2008). In tears, however, the
present study did not find statistical differences between 0.4%
and 1.5% albumin for either tropicamide or latanoprost. It is
possible that the magnitude of albumin levels is not as critical in
tears as it is in plasma, as lacrimal concentrations of albumin are
relatively small (< 2%) (Sebbag et al., 2019a) in comparison to
blood (≥ 4%) (Zeitlinger et al., 2008). Similarly, the influence of
molecular weight on drug-albumin affinity may be minimal in
tears, as most ophthalmic drugs have a relatively small and
narrow range of molecular weights (e.g. 284 Da for tropicamide,
432 Da for latanoprost). In contrast, the pH of ophthalmic
drugs is likely more impactful: pH varies from one ophthalmic
solution to another, and albumin is known to change its binding
affinity and conformation when exposed to changes in solution
pH (Kochansky et al., 2008). Here, tropicamide solution is
slightly more acidic (pH 5.8) than latanoprost solution (pH
6.7), although both solutions are near physiologic pH for the
ocular surface and may have minimal impact on albumin
affinity compared to other ophthalmic drugs such as
dorzolamide (pH 4.5). Future studies should investigate the
importance (or lack thereof) of other relevant biological factors
on albumin-drug interactions in tear fluid, such as drug
lipophilicity, viscosity, temperature at the ocular surface, fatty
acids levels in tears, and drug-drug interactions (Zeitlinger
et al., 2011).
The Study May Underestimate Drug-
Proteins Interactions and Their Impact on
Bioavailability
The present work likely underestimates the true impact of
proteins on ocular bioavailability of drugs, as the study design
has two noteworthy limitations. First, although the lag time
between albumin and drug instillation was short (< 10 s), it may
be sufficient for a portion of the administered albumin to be
washed out of the ocular surface by the time the drug mixes with
the tear film, as most of an administered eyedrop is lost to
drainage in the first 15 to 30 s (Shell, 1982; Wilson, 1999).
Second, although albumin is a major actor of drug-protein
binding on the ocular surface, other proteins play a critical role
too. Using equilibrium dialysis, Chrai and Robinson showed that
sulfisoxazole primarily binds to albumin in tears, but also a-
globulin and (to a lesser extent) g-globulin and lysozyme (Chrai
and Robinson, 1976), all of which are normal components of
tears in dogs and other species. Ultimately, the authors
recommend that future investigations be conducted with
experimental models of blood-tear barrier breakdown, such as
histamine-induced conjunctivitis in dogs (Sebbag et al., 2019a).
With such models, albumin and other key proteins are already
present on the ocular surface when the drug is administered
topically, although individual protein concentrations may vary
from one eye to another, and this variability should be accounted
FIGURE 7 | Hypothetical scenarios highlighting the importance of dose-response relationship in understanding the impact of albumin in tears on the biological
activity of an ophthalmic drug. (A) A 50% reduction in the amount of drug that can penetrate inside the eye will have a minimal effect on the biological effect of drug
A (dashed line), but a profound effect on drug B (solid line). (B) For the same drug, a 50% reduction in the amount of drug that can penetrate inside the eye will have
a minimal effect on the biological response if the initial drug concentration was high (X), but a profound effect if the initial drug concentration was relatively low (Y).
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for in the interpretation of study results. Furthermore, such
models would account for other important changes that occur
with ocular surface inflammation and that could affect drug-
protein interactions, such as altered tear volume and turnover
rate, tear film instability, and variations in mucin composition
(Rolando and Zierhut, 2001).
Strategies to Minimize Drug-Proteins
Interactions and Enhance Ocular
Bioavailability
A few strategies can be used to minimize the effects of drug-
protein interactions on the ocular surface, and thereby maximize
the drug pharmacological action by enhancing intraocular
bioavailability. First, a higher drug concentration should be
considered, especially if available commercially (e.g. tropicamide
1% instead of 0.5%), as the resulting concentration gradient of
unbound drug will be higher (Fick’s first law of diffusion). Second,
the amount of protein leakage into the tear film can be reduced by
stabilizing the blood-tear barrier in the diseased eye, a process
achieved by treating the underlying ocular disease (Sebbag et al.,
2019a) and/or using vasoprotective drugs such as calcium
dobesilate (van Bijsterveld and Janssen, 1981). Last, drug-protein
interactions can be reduced by using competitive inhibitors of
protein binding; for instance, Mikkelson and colleagues showed
that the biological activity of pilocarpine (a miotic agent)
increased 10-fold in the presence of the competitive inhibitor
cetylpyridinium chloride (Mikkelson et al., 1973b). However, the
use of competitive inhibition of albumin binding is discouraged
until the importance of albumin on the ocular surface is fully
elucidated. In fact, albumin in tear film may serve as a double-
edged sword, being detrimental to the ocular bioavailability of
topically administered medications, but also beneficial for
symptomatic relief of dry eye (Shimmura et al., 2003; Seki et al.,
2015), corneal wound healing (Shimmura et al., 2003), and anti-
oxidative and anti-inflammatory activities (Merlot et al., 2014).
Conclusion
Albumin in tears modulate the ocular bioavailability of topically
administered drugs, as observed in a “large animal” model that
shares similar anatomical and physiological features with
humans. The effect of albumin depends on the medication (e.g.
drug concentration and inherent physicochemical properties)
and was overall mild (< 10%) in the present work on healthy
canine eyes, albeit likely underestimated given the rapid tear
turnover rate following eyedrop administration. Models of ocular
surface inflammation could enable future pharmacological
studies to gain a deeper understanding of protein-drug
interactions, accounting for albumin leakage in tears as well as
other relevant factors that affect ocular surface homeostasis.
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